A randomised, double-blind, placebo-controlled study to evaluate the safety, efficacy and changes in induced sputum and blood biomarkers following daily repeat doses of inhaled GSK2269557 for 12 weeks in adult subjects diagnosed with an acute exacerbation of Chronic Obstructive Pulmonary Disease

Trial Profile

A randomised, double-blind, placebo-controlled study to evaluate the safety, efficacy and changes in induced sputum and blood biomarkers following daily repeat doses of inhaled GSK2269557 for 12 weeks in adult subjects diagnosed with an acute exacerbation of Chronic Obstructive Pulmonary Disease

Recruiting
Phase of Trial: Phase II

Latest Information Update: 08 Dec 2017

At a glance

  • Drugs Nemiralisib (Primary)
  • Indications Chronic obstructive pulmonary disease
  • Focus Pharmacodynamics; Pharmacogenomic
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 05 Dec 2017 Planned primary completion date changed from 1 Apr 2018 to 19 Oct 2018.
    • 26 Oct 2017 Planned End Date changed from 30 Apr 2018 to 19 Oct 2018.
    • 21 Mar 2017 Last checked against European Clinical Trials Database record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top